Author/Authors :
Ebeid، Samia A. نويسنده Applied Medical Chemistry Department, Medical Research Institute, Alexandria University, Alexandria, Egypt , , Abd El-Moneim، Nadia Ahmed نويسنده Department of Cancer Management and Research, Medical Research Institute, Alexandria University, Alexandria, Egypt , , Hewala، Taha I. نويسنده Department of Radiation Science, Medical Research Institute, Alexandria University, Alexandria, Egypt , , Hemida، Mahmoud A. نويسنده Department of Experimental and Clinical Surgery, Medical Research Institute, Alexandria University, Alexandria, Egypt , , Shehata، Gehan نويسنده Department of Bioinformatics and Medical Statistics, Medical Research Institute, Alexandria University, Alexandria, Egypt , , El-Taher، Nafissa نويسنده Department of Applied Medical Chemistry, Medical Research Institute, Alexandria University, Alexandria, Egypt ,
Abstract :
Background: This study intends to determine the diagnostic and prognostic roles of hypermethylation
of serum RASSF1A and protocadherin-10 promoters in females with breast cancer.
Methods: This study enrolled 80 breast cancer patients and 80 apparently normal
healthy controls. The promoter methylation status of serum RASSF1A and PCDH10
genes was investigated using methylation specific PCR.
Results: We detected no hypermethylation of the two genes in serum DNA of normal
healthy controls (100% specificity). Of the 80 patients, 50 (62.5% sensitivity) displayed
hypermethylated RASSF1A, whereas 34 (42.5% sensitivity) showed hypermethylated
PCDH10 and 64 (80% sensitivity) were hypermethylated in at least one of these two
genes. A significant association existed between hypermethylated RASSF1A and
axillary lymph node involvement. There was a significant association between hypermethylated
PCDH10 and axillary lymph node involvement, tumor size and pathological
grade. Hypermethylated RASSF1A and PCDH10 combination was significantly
associated with axillary lymph node involvement and Her-2 expression. Patients with
methylated RASSF1A or PCDH10 had significantly shorter survival rates compared
to those with unmethylated RASSF1A or PCDH10.
Conclusion:Methylated RASSF1A is superior to methylated PCDH10 for diagnosis
of breast cancer patients. Addition of methylated PCDH10 to methylated RASSF1A
significantly improves the diagnostic accuracy of RASSF1A. The present study
suggests that hypermethylated RASSF1A and PCDH10 may be independent
prognostic indicators for disease-free survival in breast cancer patients.
